Tipifarnib (IND-58359) S enantiomer
Tipifarnib (S enantiomer)
CAS: 192185-71-0
Molecular Formula: C27H22Cl2N4O
Tipifarnib (IND-58359) S enantiomer - Names and Identifiers
Tipifarnib (IND-58359) S enantiomer - Physico-chemical Properties
| Molecular Formula | C27H22Cl2N4O |
| Molar Mass | 489.4 |
| Density | 1.33±0.1 g/cm3(Predicted) |
| Boling Point | 681.7±55.0 °C(Predicted) |
| Solubility | 10 mM in DMSO |
| pKa | 7.20±0.10(Predicted) |
| Storage Condition | -20℃ |
| Use | (S)-Tipifarnib is an inactive enantiomer of Tipifarnib to be used as a negative control. |
Tipifarnib (IND-58359) S enantiomer - Reference
| Reference Show more | 1: Duluc L, Ahmetaj-Shala B, Mitchell J, Abdul-Salam VB, Mahomed AS, Aldabbous L, Oliver E, Iannone L, Dubois OD, Storck EM, Tate EW, Zhao L, Wilkins MR, Wojciak-Stothard B. Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. Cardiovasc Res. 2017 Mar 1;113(3):276-287. doi: 10.1093/cvr/cvw258. PubMed PMID: 28395021; PubMed Central PMCID: PMC5408956. 2: Shirozu K, Hirai S, Tanaka T, Hisaka S, Kaneki M, Ichinose F. Farnesyltransferase inhibitor, tipifarnib, prevents galactosamine/lipopolysaccharide-induced acute liver failure. Shock. 2014 Dec;42(6):570-577. doi: 10.1097/SHK.0000000000000239. PubMed PMID: 25046541; PubMed Central PMCID: PMC4236263. 3: Ding N, Cui XX, Gao Z, Huang H, Wei X, Du Z, Lin Y, Shih WJ, Rabson AB, Conney AH, Hu C, Zheng X. A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors. Int J Oncol. 2014 Jun;44(6):2139-45. doi: 10.3892/ijo.2014.2350. Epub 2014 Mar 19. PubMed PMID: 24647860; PubMed Central PMCID: PMC4063540. 4: Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, Balis FM. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro Oncol. 2014 May;1 |
Tipifarnib (IND-58359) S enantiomer - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.043 ml | 10.217 ml | 20.433 ml |
| 5 mM | 0.409 ml | 2.043 ml | 4.087 ml |
| 10 mM | 0.204 ml | 1.022 ml | 2.043 ml |
| 5 mM | 0.041 ml | 0.204 ml | 0.409 ml |
Last Update：2024-01-02 23:10:35
Supplier List
Spot supply
Product Name: Tipifarnib (S enantiomer) Visit Supplier Webpage Request for quotationCAS: 192185-71-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Tipifarnib (S enantiomer) Visit Supplier Webpage Request for quotationCAS: 192185-71-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History